<DOC>
	<DOCNO>NCT00319930</DOCNO>
	<brief_summary>The purpose study evaluate effect increase dos CNF1010 pharmacodynamic marker hematological response .</brief_summary>
	<brief_title>Phase 1 , Dose-Escalation , Pharmacodynamic Study IV CNF1010 ZAP-70 Positive CLL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Key 1 . Diagnosis Bcell CLL include Lymphocytosis &gt; =5,000 monoclonal Bcells/microliter coexpressing &gt; = one Bcell marker ( CD19 , CD20 , CD23 ) CD5 peripheral blood AND &lt; = 55 % prolymphocytes AND Bone marrow &gt; =30 % mononuclear cell lymphocytes 2 . ZAP70 positive CLL 3 . Intermediate High risk , poor prognosis CLL refractory fludarabinebased therapy define one following : Disease progression follow 2 cycle fludarabine OR Failure achieve PR CR least 2 cycle OR No response treatment stable disease least 2 cycle fludarabine OR Disease progression chemotherapy treatment fludarabinebased therapy OR Â· CLL patient intolerant fludarabinebased therapy . [ Intolerance define development serious medical condition occur exposure fludarabine would restrict use agent treatment patient 's CLL ( i.e. , autoimmune hemolytic anemia , myelosuppression , hypersensitivity ) ] 4 . Indication treatment define NCI Working Group Guidelines 5 . Laboratory parameter follow : Hemoglobin &gt; =10 g/dL ( may posttransfusion ) ; platelet count &gt; =50 x103/mm3 T. Bili &lt; 2 x ULN ALT AST &lt; 2 x ULN Creatinine &lt; =2 x ULN 6 . ECOG Performance Score &lt; =2 7 . For patient childproducing potential , use effective contraceptive method study 1 month follow treatment Key 1 . Pregnant nursing woman 2 . Class III IV cardiac disease define New York Heart Association Functional Classification and/or leave ventricular ejection fraction &lt; 40 % 3 . History prior radiation potentially include heart field . 4 . History myocardial infarction active ischemic heart disease within 6 month study entry 5 . History arrhythmia ( include atrial fibrillation , multifocal premature ventricular contraction , ventricular bigeminy trigeminy , ventricular tachycardia requirement antiarrhythmic ( include digoxin ) 6 . Baseline QTc &gt; =450 msec men &gt; = 470 msec woman absence correctable electrolyte imbalance 7 . Poorly control angina 8 . Congenital long QT syndrome firstdegree relative unexplained sudden death &lt; 40 year age 9 . Presence leave bundle branch block 10 . Treatment chemotherapy , monoclonal antibody radiotherapy within 28 day study entry 11 . Severe debilitate pulmonary disease 12 . Participation investigational drug study within 28 day prior CNF1010 administration . ( Patient must recover acute effect previously administer investigational agent ) 13 . Presence active malignancy exception basal cell carcinoma 14 . Active symptomatic fungal , bacterial and/or viral infection include active HIV viral ( A , B C ) hepatitis 15 . Known allergy soy 16 . Requirement concomitant therapy drug alter metabolism cytochrome P450 3A4 except lowdose warfarin implant device patency 17 . Requirement concomitant therapy drug prolong may prolong QTc interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>ZAP-70</keyword>
	<keyword>Hsp90 inhibitor</keyword>
</DOC>